The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Journal of Medicinal Chemistry

Volumn 59, Issue 4, 2016, Pages 1556-1564

  Kuntz, Kevin W ^a,b   Campbell, John E ^a   Keilhack, Heike ^a,b   Pollock, Roy M ^a,c   Knutson, Sarah K ^a,d   Porter Scott, Margaret ^a,e   Richon, Victoria M ^a,b   Sneeringer, Chris J ^a,e   Wigle, Tim J ^a,c   Allain, Christina J ^a   Majer, Christina R ^a,b   Moyer, Mikel P ^a   Copeland, Robert A ^a   Chesworth, Richard ^a  

^a EPIZYME INC   (United States)

^b Ribon Therapeutics   (United States)

^c Warp Drive Bio ^*  (United States)

^d Syros Pharmaceuticals   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL GROUP; METHYLTRANSFERASE INHIBITOR; TAZEMETOSTAT; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE; MOLECULAR LIBRARY; POLYCOMB REPRESSIVE COMPLEX 2;

ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; HISTONE METHYLATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; METHYLATION; MOLECULAR LIBRARY; PHARMACOKINETICS; PHARMACOLOGY; PROTEIN PROCESSING;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HISTONES; HUMANS; METHYLATION; MICE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84959440141     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01501     Document Type: Article

References (22)

1. Musselman, C. A.; Lalonde, M.; Coîté, J.; Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers Nat. Struct. Mol. Biol. 2012, 19, 1218-1227 10.1038/nsmb.2436
2. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 2010, 42, 181-185 10.1038/ng.518
3. Sneeringer, C. J.; Porter-Scott, M.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. R.; Copeland, R. A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20980-20985 10.1073/pnas.1012525107
4. Del Rizzo, P. A.; Couture, J.-F.; Dirk, L. M. A.; Strunk, B. S.; Roiko, M. S.; Brunzelle, J. S.; Houtz, R. L.; Trievel, R. C. SET7/9 Catalytic Mutants Reveal the Role of Active Site Water Molecules in Lysine Multiple Methylation J. Biol. Chem. 2010, 285, 31849-31858 10.1074/jbc.M110.114587
5. Couture, J.; Dirk, L. M. A.; Brunzelle, J. S.; Houtz, R. L.; Trievel, R. C. Structural origins for the product specificity of SET domain protein methyltransferases Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 20659-20664 10.1073/pnas.0806712105
6. Chan-Penebre, E.; Kuplast, K. G.; Majer, C. R.; Boriack-Sjodin, P. A.; Wigle, T. J.; Johnston, L. D.; Rioux, N.; Munchhof, M. J.; Jin, L.; Jacques, S. L.; West, K. A.; Lingaraj, T.; Stickland, K.; Ribich, S. A.; Raimondi, A.; Scott, M. P.; Waters, N. J.; Pollock, R. M.; Smith, J. J.; Barbash, O.; Pappalardi, M.; Ho, T. F.; Nurse, K.; Oza, K. P.; Gallagher, K. T.; Kruger, R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R.; Duncan, K. W. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Nat. Chem. Biol. 2015, 11, 432-437 10.1038/nchembio.1810
7. Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl Effects on Protein-Ligand Binding J. Med. Chem. 2012, 55, 4489-4500 10.1021/jm3003697
8. Barreiro, E. J.; Kummerle, A. E.; Fraga, C. A. M. The Methylation Effect in Medicinal Chemistry Chem. Rev. 2011, 111, 5215-5246 10.1021/cr200060g
9. Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.; Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song, J.; Porter-Scott, M.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer, M.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.; Kuntz, K. W. A Selective Inhibitor of EZH2 blocks H3K27 methylation and Kills Mutant Lymphoma Cells Nat. Chem. Biol. 2012, 8, 890-896 10.1038/nchembio.1084
10. Gehling, V. S.; Vaswani, R. G.; Nasveschuk, C. G.; Duplessis, M.; Iyer, P.; Balasubramanian, S.; Zhao, F.; Good, A. C.; Camp-bell, R.; Lee, C.; Dakin, L. A.; Cook, A. S.; Gagnon, A.; Harmange, J.; Audia, J. E.; Cummings, R. T.; Normant, E.; Trojer, P.; Albrecht, B. K. Discovery, design, and synthesis of indole-based EZH2 inhibitors Bioorg. Med. Chem. Lett. 2015, 25, 3644-3649 10.1016/j.bmcl.2015.06.056
11. Verma, S. K.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.; Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.; Ott, H. M.; Van Aller, G. S.; Machutta, C. A.; Diaz, E.; Jiang, Y.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of Potent, Selective Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2 ACS Med. Chem. Lett. 2012, 3, 1091-1096 10.1021/ml3003346
12. Qi, W.; Chan, H.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J.-H.; Yan, X.; Fang, J.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z.; Li, G.; Yang, T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C. X.; Atadja, P.; Li, E. Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cell proliferation Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 21360-21365 10.1073/pnas.1210371110
13. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd ed.; Wiley: Hoboken, NJ, 2013.
14. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740 10.1021/jm901137j
15. Lor, L. A.; Schneck, J.; McNulty, D. E.; Diaz, E.; Brandt, M.; Thrall, S. H.; Schwartz, B. A simple assay for detection of small-molecule redox activity J. Biomol. Screening 2007, 12, 881-890 10.1177/1087057107304113
16. Thorne, N.; Auld, D. S.; Inglese, J. Apparent Activity in High-Throughput Screening: Origins of Compound-Dependent Assay Interference Curr. Opin. Chem. Biol. 2010, 14, 315-324 10.1016/j.cbpa.2010.03.020
17. Kuntz, K. W.; Chesworth, R.; Duncan, K. W.; Keilhack, H.; Warholic, N.; Klaus, C.; Zheng, W.; Seki, M.; Shirotori, S.; Ka-wano, S. Aryl-or heteroaryl-substituted benzamide compounds as anticancer agents and their preparation. WO 2012142504 A1, October 18, 2012.
18. Edwards, M. P.; Kumpf, R. A.; Kung, P.; Mcalpine, I. J.; Ninkovic, S.; Rui, E. Y.; Sutton, S. C.; Tatlock, J. H.; Wythes, M. J.; Zehnder, L. R. Aryl and heteroaryl fused lactams. WO 2014/097041 A1, June 26, 2014.
19. Knutson, S. K.; Kawano, S.; Minoshima, Y.; Warholic, N. M.; Huang, K.; Xiao, Y.; Kadowaki, T.; Uesugi, M.; Kuznetsov, G.; Kumar, N.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Waters, N. J.; Smith, J. J.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Uenaka, T.; Pollock, R. M.; Kuntz, K. W.; Yokoi, A.; Keilhack, H. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma Mol. Cancer Ther. 2014, 13, 842-854 10.1158/1535-7163.MCT-13-0773
20. Knutson, S. K.; Warholic, N. M.; Johnston, L. D.; Klaus, C. R.; Wigle, T. J.; Iwanowicz, D.; Littlefield, B. A.; Porter-Scott, M.; Smith, J.; Moyer, M. P.; Copeland, R. A.; Pollock, R. M.; Kuntz, K. W.; Raimondi, A.; Keilhack, H. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS One 2014, 9, e111840 10.1371/journal.pone.0111840
21. Knutson, S. K.; Warholic, N. M.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M.; Kuntz, K. W.; Keilhack, H. Durable Tumor Regression in Genetically Altered Malignant Rhabdoid Tumors by Inhibition of Methyltransferase EZH2 Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 7922-7927 10.1073/pnas.1303800110
22. Ribrag, V.; Soria, J.; Reyderman, L.; Kraljevic, S.; Chen, R.; Salazar, P.; Kuznetsov, G.; Keilhack, H.; Waters, N.; Hedrick, E.; Ottesen, L. H.; Italiano, A. Phase 1 Study of E7438 (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Dose Determination and Preliminary Activity in Non-Hodgkin Lymphoma Hematol. Oncol. 2015, 33, 179